Pluristem Life Systems, Inc. (OTCBB:PLRS - News), a biotechnology company dedicated to the expansion of stem cells from umbilical cord blood to address a myriad of fatal illnesses, today announced that the Board of Directors appointed Dr. Menachem (Mendi) Ze'evi as Chief Executive Officer.

Dr. Ze'evi has a wealth of expertise in the management, growth, and development of biotechnology and pharmaceutical companies. From 2000 to 2003, Dr. Ze'evi acted as Chief Executive Officer of Polyheal Ltd., a biotechnology company specializing in wound healing and tissue regeneration. He was responsible for all aspects of business development, R&D, registration, production, quality assurance, quality control and clinical development. During Dr. Ze'evi's tenure at Polyheal he obtained CE Mark Certification (European marketing approval) for the company's first product -- medical device. In addition, he interacted extensively with potential strategic partners, the U.S. FDA and European Health Authorities.

From 1987 to 1999, Dr. Ze'evi held the positions of Vice President of Process Development and Technology and Vice President of Operations Technical Support for InterPharm Laboratories, a subsidiary of the Swiss biotechnology company, Serono International S.A. (NASDAQ: SRA - News). As VP of Operations Technical Support, he managed a staff of twenty-five in operations, development and research. Dr. Ze'evi led his group who scaled up the production processes, performed process validation and supported the registration of files, optimized processes and analytical tests to decrease costs and increase yields.

During 1981 to 1987 Dr. Ze'evi held the position of VP Production and Development at BioTechnology General, a subsidiary of the U.S. based Savient Pharmaceuticals Inc. (NASDAQ: SVNT - News). As VP Production and Development he managed a staff of forty-five in operations, development and engineering. Dr. Ze'evi led his group who developed recombinant proteins production processes, scaled up production and the design of the company's production plant.

Dr. Ze'evi holds a diploma in Business Administration from the Technion -- Israel Institute of Technology, was a postdoctoral fellow the Rockefeller University in New York, holds a Ph.D. in Biochemistry from the Weizmann Institute of Science and an M.Sc. in Microbiology from Tel Aviv University. His research has been publicized worldwide and he holds 13 patents in the field of biotechnology.

"Dr. Ze'evi possesses the very unique combination of exceptional business acumen, leadership experience in pre-clinical and clinical trial processes and the ability to manage a company using his vision and experience with the investment community. As Pluristem enters the clinical stage and negotiates financing and other transactions in its growth plan, we are honored to have such a highly respected and knowledgeable leader join us in our mission," stated Doron Shorrer, Chairman of the Board.

Dr. Irit Arbel resigned as Company CEO for personal reasons.

About Pluristem

Pluristem is a biotechnology company dedicated to the development of stem cell expansion technology. The Company is concentrating on the expansion of cord blood hematopoietic stem cells (blood and immune system cells) to provide vital stem cell expansion services to blood banks and transplants centers in the U.S. and Europe.

For more information, visit the Company's website at: www.pluristem.com.

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Pluristem Life Systems, Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include statements regarding our developing stem cell technology into a useful product which, among other things, can treat fatal illnesses and obtaining patent protection in the US and worldwide for our technology. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. For further risk factors see the Company's latest 10-KSB filed with the SEC.